Clinical-stage Potential ADOCIA is a clinical-stage biotech focused on improving therapeutic proteins with its BioChaperone platform, creating opportunities to partner on formulation enhancements for diabetes and obesity therapies in development or late-stage trials.

Productivity Platform The proprietary BioChaperone technology could be licensed or co-developed with other pharma players seeking to enhance efficacy and patient safety of existing proteins, opening partnerships with manufacturers of insulin, GLP-1 therapies, or other protein drugs.

Financial Readiness With funding of around $56M and revenue in the low single digits, ADOCIA may be open to strategic collaborations, milestone-driven deals, or joint development agreements to accelerate pipeline programs while sharing risk.

Targeted Markets Focus on diabetes and obesity presents clear growth avenues; selling opportunities exist with devices, delivery systems, or companion diagnostics that complement improved protein formulations and patient usability.

Global Reach Listed on Euronext and pursuing international biotech partnerships, ADOCIA can benefit from cross-border collaborations, licensing, or contract development/manufacturing organizations to scale formulation platforms across markets.